Plain-English translation of NCT02140255 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether starting babies born with HIV on intensive combination antiretroviral therapy (multiple HIV medications together) within the first 48 hours of life can help them achieve HIV remission — meaning the virus becomes undetectable in their blood. The study will test seven different medication combinations to find which approach works best. The hope is that treating HIV this early and aggressively in newborns might give their developing immune systems the best chance to control the infection long-term.
Most babies born with HIV do well on standard treatment, but the virus persists in their bodies for life. Researchers want to see if treating the infection much more intensively and starting even earlier — within the first hours or days of life — might help some babies's bodies actually clear the virus or keep it suppressed without lifelong medication.
You likely qualify if…
You likely don't qualify if…
If your baby is enrolled, you will start one of seven different combination HIV medication regimens within 48 hours of birth. Your baby will have frequent blood tests and clinic visits over many months to check how well the medications are working and to monitor for any side effects. Some medication regimens will change when your baby reaches certain milestones (like 28 days old). The study involves multiple steps over approximately two years, with careful monitoring to see whether the virus becomes undetectable and stays that way.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
United States